These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 11034267)
1. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ward SB; Sjostrom L; Ujhelyi MR Ther Drug Monit; 2000 Oct; 22(5):599-607. PubMed ID: 11034267 [TBL] [Abstract][Full Text] [Related]
2. Digoxin and digoxin derivative induced arrhythmias: in vitro binding and in vivo abolition of arrhythmias by digoxin immune Fab (DIGIBAND). Cambridge D; Morgan CR; Allen G Cardiovasc Res; 1992 Sep; 26(9):906-11. PubMed ID: 1451168 [TBL] [Abstract][Full Text] [Related]
3. Effect of digoxin fab antibody on the measurement of total and free digitoxin by fluorescence polarization and a new chemiluminescent immunoassay. Dasgupta A; Wells A; Datta P Ther Drug Monit; 1999 Apr; 21(2):251-5. PubMed ID: 10217348 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of severe digoxin intoxication with antidote]. Houlberg E; Blicher TM Ugeskr Laeger; 2008 Oct; 170(42):3339. PubMed ID: 18940174 [TBL] [Abstract][Full Text] [Related]
5. Hemodynamic effects of the Fab fragment of digoxin antibody (digibind) in corticotropin (ACTH)-induced hypertension. Li M; Wen C; Whitworth JA Am J Hypertens; 1997 Mar; 10(3):332-6. PubMed ID: 9056691 [TBL] [Abstract][Full Text] [Related]
6. Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind). Dasgupta A; Szelei-Stevens KA Am J Clin Pathol; 2004 Feb; 121(2):276-81. PubMed ID: 14983943 [TBL] [Abstract][Full Text] [Related]
7. The Fab fragment of anti-digoxin antibody (digibind) binds digitoxin-like immunoreactive components of Chinese medicine Chan Su: monitoring the effect by measuring free digitoxin. Dasgupta A; Lopez AE; Wells A; Olsen M; Actor J Clin Chim Acta; 2001 Jul; 309(1):91-5. PubMed ID: 11408010 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Ujhelyi MR; Robert S Clin Pharmacokinet; 1995 Jun; 28(6):483-93. PubMed ID: 7656506 [TBL] [Abstract][Full Text] [Related]
9. Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind). Jortani SA; Pinar A; Johnson NA; Valdes R Clin Chim Acta; 1999 May; 283(1-2):159-69. PubMed ID: 10404740 [TBL] [Abstract][Full Text] [Related]
10. Serum digoxin in the presence of digibind: determination of digoxin by the Abbott AxSYM and Baxter Stratus II immunoassays by direct analysis without pretreatment of serum samples. Ocal IT; Green TR Clin Chem; 1998 Sep; 44(9):1947-50. PubMed ID: 9732982 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations. Wagner JG; Stoll RG; Weidler DJ; Ayres JW; Hallmark MR; Sakmar E; Yacobi A J Pharmacokinet Biopharm; 1979 Apr; 7(2):147-58. PubMed ID: 20218011 [TBL] [Abstract][Full Text] [Related]
12. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ujhelyi MR; Robert S; Cummings DM; Colucci RD; Green PJ; Sailstad J; Vlasses PH; Zarowitz BJ Ann Intern Med; 1993 Aug; 119(4):273-7. PubMed ID: 8328735 [TBL] [Abstract][Full Text] [Related]
13. Disposition of digoxin immune Fab in patients with kidney failure. Ujhelyi MR; Robert S; Cummings DM; Colucci RD; Sailstad JM; Vlasses PH; Findlay JW; Zarowitz BJ Clin Pharmacol Ther; 1993 Oct; 54(4):388-94. PubMed ID: 8222481 [TBL] [Abstract][Full Text] [Related]
14. Fab antibody fragments: some applications in clinical toxicology. Flanagan RJ; Jones AL Drug Saf; 2004; 27(14):1115-33. PubMed ID: 15554746 [TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment. Allen NM; Dunham GD; Sailstad JM; Findlay JW DICP; 1991 Dec; 25(12):1315-20. PubMed ID: 1815424 [TBL] [Abstract][Full Text] [Related]
16. The use of an enzyme-linked immunosorbent assay to study the disposition of sheep digoxin-specific immunoglobulin G and Fab fragments in the rat. Johnston PC; Stevenson IH; Hewick DS Clin Exp Immunol; 1988 Dec; 74(3):489-93. PubMed ID: 3233793 [TBL] [Abstract][Full Text] [Related]
17. Effects of digoxin-specific antibody Fab fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats. Kaide J; Ura N; Torii T; Nakagawa M; Takada T; Shimamoto K Am J Hypertens; 1999 Jun; 12(6):611-9. PubMed ID: 10371371 [TBL] [Abstract][Full Text] [Related]
18. The clinical use of Digibind in digitalis toxicity. Morgera RV R I Med J (1976); 1991 Mar; 74(3):117-9. PubMed ID: 2038646 [TBL] [Abstract][Full Text] [Related]
19. Effect of Indian Ayurvedic medicine Ashwagandha on measurement of serum digoxin and 11 commonly monitored drugs using immunoassays: study of protein binding and interaction with Digibind. Dasgupta A; Peterson A; Wells A; Actor JK Arch Pathol Lab Med; 2007 Aug; 131(8):1298-303. PubMed ID: 17683192 [TBL] [Abstract][Full Text] [Related]
20. Comparison of non-digitalis binding properties of digoxin-specific Fabs using direct binding methods. Pullen MA; Harpel MR; Danoff TM; Brooks DP J Immunol Methods; 2008 Jul; 336(2):235-41. PubMed ID: 18555269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]